Reneo Pharmaceuticals is developing therapies for patients with rare genetic mitochondrial diseases. Mitochondrial dysfunction is linked with various human diseases. Reneo is investigating the basic biology behind these diseases, with a particular focus on ATP production, to assess the most effective ways to treat the disease. This involves various in vitro experiments to screen for effective small molecules that can be used as human therapeutics. To expand further, Reneo is merging with OnKure with a focus on oncology targets.

Reneo Pharmaceuticals

Drug notes:

About:

Jobs: